Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
Kamada (NASDAQ: KMDA) will release its fiscal year and fourth quarter 2025 financial results on Wednesday, March 11, 2026 before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kamada (NASDAQ: KMDA) will release its fiscal year and fourth quarter 2025 financial results on Wednesday, March 11, 2026 before U.S. markets open. Management will host an investor conference call at 8:30am Eastern Time the same day and will webcast the discussion live.
Investors may join by phone (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) using conference ID 13758519 or via the live webcast link provided by the company.
Details
News Market Reaction – KMDA
On Mar 4, the day this news came out, KMDA closed 2.91% above the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- Fiscal year end
- December 31, 2025
- Period covered by upcoming FY and Q4 2025 results
- Earnings release date
- March 11, 2026
- Scheduled FY and Q4 2025 results release before U.S. market open
- Conference call time
- 8:30am Eastern Time
- Time of management call to discuss FY and Q4 2025 results
- US dial-in number
- 1-877-407-0792
- Domestic U.S. access number for earnings call
Historical Context
-
Issued 2026 revenue and adjusted EBITDA guidance with double-digit growth targets.
-
Announced $10–$14M extension of Canadian supply tender securing future sales.
-
Discontinued Phase 3 InnovAATe inhaled AAT trial after futility analysis.
-
Reported strong Q3 and nine‑month 2025 results with >30% profitability growth.
-
First patient enrolled in SHIELD CYTOGAM trial for CMV prevention in transplant.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to Host Conference Call at 8:30am ET
REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March 11, 2026.
Kamada’s management will host an investment community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689- 8263 (International) using conference I.D. 13758519. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1751343&tp_key=e8c73d1516.
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.